RESUMO
OBJETIVOS: Interações medicamentosas ocorrem quando os efeitos e/ou a toxicidade de um fármaco são alterados pela presença de outro. São geralmente imprevistas e indesejáveis. Realizado estudo com objetivo de verificar a prevalência e o valor clínico das interações medicamentosas potenciais em unidades de terapia intensiva. MÉTODOS: Incluídos todos pacientes de três unidades de terapia intensiva em um período de 2 meses, analisados transversalmente. Foram excluídos aqueles com tempo de permanência menor que 2 dias. Os dados foram tabulados de acordo com as combinações de fármacos observadas no período de 24 horas. A presença e o valor clínico das interações medicamentosas potenciais foram conferidos ao final do seguimento. RESULTADOS: Analisados 140 pacientes, 67,1 por cento apresentaram alguma interações medicamentosas potenciais significativa e das 1069 prescrições, 39,2 por cento tiveram este achado. De 188 interações medicamentosas potenciais diferentes, 29 foram consideradas altamente significativas. Por análise univariada, observou-se no grupo que apresentou interação significativa maior quantidade de medicamentos, fármacos/dia, número de médicos prescritores e tempo de internação na unidade de teapia intensiva. Por modelo de regressão logística multivariada, apenas o número de fármacos/dia correlacionou-se com o aumento do risco de interação medicamentosa potencial significativa (p = 0.0011); o uso de mais que 6 medicamentos/dia aumenta em 9.8 vezes este risco. CONCLUSÕES: Pacientes em unidades de terapia intensiva estão submetidos a alto risco de interações medicamentosas potenciais e o número de fármacos/dia é condição com alto valor preditivo positivo para tal. Os intensivistas devem ser alertados para o reconhecimento do problema e criados mecanismos para o manejo adequado e prudente, diminuindo iatrogenias.
OBJECTIVES: Drug interactions occur when effects and/or toxicity of a drug are affected by presence of another drug. They are usually unpredictable and undesirable. A study was conducted to verify the prevalence and clinical value of potential drug interactions in intensive care units METHODS: All patients, of three intensive care units were included in a cross-sectional study, over a period of two months. Patients with less than a 2 days length of stay were excluded. Data were collected from twenty-four hour prescriptions and all possible paired combinations drug-drug were recorded. Prevalence and clinical value (significance) were checked at the end of follow-up. RESULTS: One hundred and forty patients were analyzed, 67.1 percent presented with some significant potential drug interactions and of the 1069 prescriptions, 39.2 percent disclosed the same potential. Of 188 different potential drug interactions, 29 were considered highly significant. Univariate analysis showed that in the group with significant potential drug interactions a higher number of different drugs, drugs/day had been used, there were more prescribing physicians and extended stay in intensive care units. Adjusted to the multivariate logistic regression model, only the number of drugs/day correlated with increased risk of significant potential drug interaction (p = 0.0011) and, furthermore that use of more than 6 drugs/day increased relative risk by 9.8 times. CONCLUSIONS: Critically ill patients are submitted to high risk of potential drug interactions and the number of drugs/day has a high positive predictive value for these interactions. Therefore, it is imperative that critical care physicians be constantly alert to recognize this problem and provide appropriate mechanisms for management, thereby reducing adverse outcomes.
Assuntos
Interações Medicamentosas , Pacientes Internados , Unidades de Terapia IntensivaRESUMO
OBJECTIVES: Drug interactions occur when effects and/or toxicity of a drug are affected by presence of another drug. They are usually unpredictable and undesirable. A study was conducted to verify the prevalence and clinical value of potential drug interactions in intensive care units METHODS: All patients, of three intensive care units were included in a cross-sectional study, over a period of two months. Patients with less than a 2 days length of stay were excluded. Data were collected from twenty-four hour prescriptions and all possible paired combinations drug-drug were recorded. Prevalence and clinical value (significance) were checked at the end of follow-up. RESULTS: One hundred and forty patients were analyzed, 67.1% presented with some significant potential drug interactions and of the 1069 prescriptions, 39.2% disclosed the same potential. Of 188 different potential drug interactions, 29 were considered highly significant. Univariate analysis showed that in the group with significant potential drug interactions a higher number of different drugs, drugs/day had been used, there were more prescribing physicians and extended stay in intensive care units. Adjusted to the multivariate logistic regression model, only the number of drugs/day correlated with increased risk of significant potential drug interaction (p = 0.0011) and, furthermore that use of more than 6 drugs/day increased relative risk by 9.8 times. CONCLUSIONS: Critically ill patients are submitted to high risk of potential drug interactions and the number of drugs/day has a high positive predictive value for these interactions. Therefore, it is imperative that critical care physicians be constantly alert to recognize this problem and provide appropriate mechanisms for management, thereby reducing adverse outcomes.
RESUMO
Introdução: O referenciamento tardio (RT) para o acompanhamento nefrológico em pacientes com insuficiência renal crônica (IRC) está associado com um aumento da mortalidade. Em nosso meio, há dados escassos sobre o assunto, em especial com respeito à sua relação com a fonte de financiamento do acompanhamento especializado. Método: Análise retrospectiva de dados de pacientes em uma unidade satélite de hemodiálise. Considerou-se RT um período inferior a 120 dias entre o atendimento nefrológico e o início da hemodiálise (HD). Resultados: O RT aconteceu em 36,6% da amostra, foi associado com início de hemodiálise em caráter emergencial, com acesso por cateter venoso central e maior mortalidade (46,7% vs. 19,2%, p < 0,05,comparando ao grupo de eferenciamento precoce). A fonte de financiamento para 1/3 da amostra foi o Sistema Único de Saúde (SUS). Desse grupo, 66,7% foram referenciados tardiamente, apresentaram mortalidade de 21,4% nos primeiros três meses de tratamento, e 71% iniciaram a HD em regime de internação hospitalar. Discussão e Conclusões: Pacientes com insuficiência renal crônica referenciados tardiamente ao tratamento nefrológicoapresentam maior mortalidade, início do tratamento em caráter emergencial por acesso vascular temporário. Houve associação entre referenciamentotardio e o financiamento pelo SUS. Novos estudos são necessários para verificar a disponibilidade de atendimento especializado pelo SUS para a consolidação de uma política pública de atendimento ao renal crônico.
Introduction: Late referral (LR) of chronic renal failure patients to the nephrologist is related to increased mortality. There is little data in our country, particularly related to LR and the financial source of medical treatment. Methods: This was a retrospective analysis of patients reports in a non-hospitalhemodialysis unit. LR was defined when there was a period of less than 120 days between referral and initiation of hemodialysis. Results: LR occurred in36.6% of the patients and was related to the need of emergency hemodialysis (HD), use of central venous access, and increased mortality (46.7% vs. 19.2%,p < 0.05, in comparison to the early referral group). The funding for 33.3% of the patients was provided by the public health system (SUS). In this group of patients, 66.7% presented LR and increased mortality in the first 3 months of HD (21.4%). Moreover, 71% initiated HD in a hospital setting. Discussion and Conclusions: Chronic renal failure patients with LR presented increased mortality, need for emergency HD and temporary vascular access. There was an association between LR and public funding. Further studies are necessary to evaluate the availability of nephrology assistance by the public health system, in order to promote better care for the chronic renal failure patient.